EXS 74539
Alternative Names: '539; EXS-74539Latest Information Update: 27 May 2024
At a glance
- Originator Bristol-Myers Squibb; Exscientia
- Developer Exscientia
- Class Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Small cell lung cancer
Most Recent Events
- 21 May 2024 Exscientia plans to submit an IND application for EXS 74539 in the third quarter of 2024
- 21 May 2024 Exscientia plans a phase I/II trial for Acute myeloid leukaemia in the US, by the end of 2024
- 24 Oct 2023 Preclinical trials in Small cell lung cancer in United Kingdom (PO) prior to October 2023 (Exsientia pipeline, October 2023)